Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

Elevated levels of PtdIns5P in NPM-ALK transformed cells: implication of PIKfyve.

Coronas S, Lagarrigue F, Ramel D, Chicanne G, Delsol G, Payrastre B, Tronchère H.

Biochem Biophys Res Commun. 2008 Jul 25;372(2):351-5. doi: 10.1016/j.bbrc.2008.05.062. Epub 2008 May 22.

PMID:
18501703
[PubMed - indexed for MEDLINE]
2.

The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness.

Dupuis-Coronas S, Lagarrigue F, Ramel D, Chicanne G, Saland E, Gaits-Iacovoni F, Payrastre B, Tronchère H.

J Biol Chem. 2011 Sep 16;286(37):32105-14. doi: 10.1074/jbc.M111.227512. Epub 2011 Jul 7.

PMID:
21737449
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.

Chikamori M, Fujimoto J, Tokai-Nishizumi N, Yamamoto T.

Oncogene. 2007 May 3;26(20):2950-4. Epub 2006 Nov 6.

PMID:
17086210
[PubMed - indexed for MEDLINE]
4.

HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.

Bergalet J, Fawal M, Lopez C, Desjobert C, Lamant L, Delsol G, Morello D, Espinos E.

Mol Cancer Res. 2011 Apr;9(4):485-96. doi: 10.1158/1541-7786.MCR-10-0351. Epub 2011 Feb 22.

PMID:
21343335
[PubMed - indexed for MEDLINE]
Free Article
5.

NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.

Slupianek A, Skorski T.

Exp Hematol. 2004 Dec;32(12):1265-71.

PMID:
15588951
[PubMed - indexed for MEDLINE]
6.

A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.

Fawal M, Armstrong F, Ollier S, Dupont H, Touriol C, Monsarrat B, Delsol G, Payrastre B, Morello D.

Blood. 2006 Oct 15;108(8):2780-8. Epub 2006 Jul 11.

PMID:
16835382
[PubMed - indexed for MEDLINE]
Free Article
7.

Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.

Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA.

Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9964-9. Epub 2006 Jun 9.

PMID:
16766651
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.

Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G, Payrastre B, Gaits-Iacovoni F.

Oncogene. 2008 Apr 24;27(19):2728-36. Epub 2007 Nov 12.

PMID:
17998938
[PubMed - indexed for MEDLINE]
9.
10.

The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.

Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiros LJ, Szankasi P, Elenitoba-Johnson KS.

Blood. 2009 Aug 20;114(8):1585-95. doi: 10.1182/blood-2009-02-204735. Epub 2009 Jun 16.

PMID:
19531656
[PubMed - indexed for MEDLINE]
Free Article
11.

Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.

Hsu FY, Zhao Y, Anderson WF, Johnston PB.

Cancer Invest. 2007 Jun;25(4):240-8.

PMID:
17612934
[PubMed - indexed for MEDLINE]
12.

Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.

Jäger R, Hahne J, Jacob A, Egert A, Schenkel J, Wernert N, Schorle H, Wellmann A.

Anticancer Res. 2005 Sep-Oct;25(5):3191-6.

PMID:
16101126
[PubMed - indexed for MEDLINE]
Free Article
13.

[Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].

Merz H, Lange K, Nadrowitz R, Uckert W, Blankenstein T, Feller AC.

Verh Dtsch Ges Pathol. 2003;87:224-31. German.

PMID:
16888916
[PubMed - indexed for MEDLINE]
14.

Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.

Turner SD, Tooze R, Maclennan K, Alexander DR.

Oncogene. 2003 Oct 30;22(49):7750-61.

PMID:
14586401
[PubMed - indexed for MEDLINE]
15.

ALK-mediated Na+/H+ exchanger-dependent intracellular alkalinization: does it matter for oncogenesis?

Turturro F, Driscoll M, Friday E, Welbourne T.

Haematologica. 2007 May;92(5):706-7.

PMID:
17488701
[PubMed - indexed for MEDLINE]
Free Article
16.

A novel HPLC-based approach makes possible the spatial characterization of cellular PtdIns5P and other phosphoinositides.

Sarkes D, Rameh LE.

Biochem J. 2010 May 27;428(3):375-84. doi: 10.1042/BJ20100129.

PMID:
20370717
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.

Thornber K, Colomba A, Ceccato L, Delsol G, Payrastre B, Gaits-Iacovoni F.

Oncogene. 2009 Jul 23;28(29):2690-6. doi: 10.1038/onc.2009.125. Epub 2009 Jun 8.

PMID:
19503098
[PubMed - indexed for MEDLINE]
18.

The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.

Bonvini P, Zorzi E, Mussolin L, Monaco G, Pigazzi M, Basso G, Rosolen A.

Haematologica. 2009 Jul;94(7):944-55. doi: 10.3324/haematol.2008.004861. Epub 2009 Jun 16.

PMID:
19535344
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Functional dissociation between PIKfyve-synthesized PtdIns5P and PtdIns(3,5)P2 by means of the PIKfyve inhibitor YM201636.

Sbrissa D, Ikonomov OC, Filios C, Delvecchio K, Shisheva A.

Am J Physiol Cell Physiol. 2012 Aug 15;303(4):C436-46. doi: 10.1152/ajpcell.00105.2012. Epub 2012 May 23.

PMID:
22621786
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

PtdIns5P: news and views of its appearance, disappearance and deeds.

Shisheva A.

Arch Biochem Biophys. 2013 Oct 15;538(2):171-80. doi: 10.1016/j.abb.2013.07.023. Epub 2013 Aug 2. Review.

PMID:
23916588
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk